BLI-489 / Pfizer - LARVOL DELTA

Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales. (PubMed, J Antimicrob Chemother) - "The novel β-lactamase inhibitor BLI-489 possesses a synergistic effect against diverse carbapenemase-producing CRE combined with imipenem or meropenem."

Journal • Infectious Disease • Pneumonia

[VIRTUAL] Antimicrobial Activity of the β-Lactam-BLI-489 Combinations Against Burkholderia Species (WMF 2021) - "β-Lactam antibiotics such as ceftazidime or meropenem are commonly used to treat infections caused by Burkholderia species. BLI-489 is a potent inhibitor of PenA1 and AmpC1 resulting in considerable antimicrobial activity when tested in combination with a carbapenem against a panel of clinical isolates of Bcc and B. gladioli. β-Lactam-BLI-489 combinations demonstrated promising in vitro activity against Bcc and B. gladioli."

Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii. (PubMed, J Antimicrob Chemother) - "Imipenem combined with BLI-489 has synergistic effects against CHDL-producing CRAb isolates."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

In vitro and in vivo activities of imipenem in combination with the penem beta-lactamase inhibitor BLI-489 against carbapenem-resistant Acinetobacter baumannii (ECCMID 2019) - "Combinations of penem inhibitor BLI-489 and imipenem exhibited in-vitro and in-vivo synergistic effects against CHDL-producing CRAb."

Combination therapy • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases